S-545-119
Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.
Sponsored by Catherine Cortez Masto (D-NV)
What it does
This bill would add xylazine — a veterinary sedative increasingly found mixed with illicit fentanyl — to Schedule III of the Controlled Substances Act. It would restrict legal possession to veterinarians, licensed pharmacies acting on veterinary prescriptions, and authorized animal-control or wildlife programs. The bill would also require the DEA to track xylazine through its existing drug monitoring system (ARCOS), direct the U.S. Sentencing Commission to review and potentially update sentencing guidelines for xylazine-related offenses, and mandate multiple reports to Congress on the drug's prevalence and trafficking patterns.
Who benefits
People who use drugs and are at risk of xylazine exposure in the illicit drug supply, particularly fentanyl users, who may benefit from increased supply-chain tracking and enforcement. Emergency medical personnel and harm reduction workers who would gain clearer legal frameworks around the substance. Law enforcement agencies that would gain new tools to prosecute xylazine trafficking. Veterinarians and licensed animal-care professionals whose legitimate use would be explicitly protected. Communities with high rates of overdose deaths involving xylazine-adulterated drugs.
Who is hurt
People who use drugs illicitly and possess xylazine, who would face new federal criminal exposure. Farmers, ranchers, and animal caretakers who currently use xylazine without a formal veterinary prescription and would need to obtain one. Xylazine manufacturers who would face new regulatory compliance costs, including registration, recordkeeping, and labeling requirements (though the bill provides transition periods). Researchers studying xylazine outside of approved channels who may face additional regulatory hurdles. Public defenders and legal aid organizations that may see increased caseloads from new federal drug charges.
Supporters argue
Supporters argue that xylazine — commonly called "tranq" — has become a major driver of overdose deaths because it does not respond to naloxone, the standard opioid reversal medication, and is now detected in a significant share of fentanyl-related overdose deaths in cities like Philadelphia and Baltimore. They contend that Schedule III placement gives law enforcement the legal authority to prosecute traffickers who deliberately adulterate the drug supply, while the bill's explicit carve-outs protect the veterinary and agricultural communities that depend on xylazine for legitimate animal care. The broad bipartisan sponsorship — spanning more than 30 senators from both parties — reflects consensus that the current unscheduled status of xylazine creates an enforcement gap that traffickers exploit.
Opponents argue
Opponents argue that scheduling xylazine as a controlled substance will do little to reduce its presence in the illicit drug supply, since it is already widely available and inexpensive, and that criminalization may deter people who use drugs from seeking emergency medical help out of fear of prosecution. They contend that Schedule III placement — rather than a lower schedule or a non-criminal regulatory approach — imposes new criminal penalties on people struggling with addiction without addressing the underlying public health crisis, and that evidence from prior drug scheduling decisions shows supply-side enforcement alone does not reduce drug-related harm. Critics also note that the bill's sentencing guidelines directive could result in additional mandatory or enhanced penalties that disproportionately affect low-level users and small-scale distributors.